“D-M-T” but to the tune of “TNT” by AC/DC

New paper from the Michigan Psychedelic Center (M-PsyC) and collaborators! "Best practices for first psychedelic experiences: Harm reduction advice from the psychedelic community"

Best practices for first psychedelic experiences: harm reduction advice from the psychedelic community link.springer.com/article/10.1...

🚨Publication alert! 🚨 Why does stress drive psychopathology & transdiagnostic disease? We present the Allostatic Triage Model of Psychopathology (ATP Model), which explains stress-induced transdiagnostic disease pathogenesis through a bioenergetic lens. www.sciencedirect.com/science/arti...

Our latest manuscript (from www.omarlab.org) is now published and available online -- Long lasting enhancement in reversal learning after a single psychedelic dose pmc.ncbi.nlm.nih.gov/articles/PMC...

Reframing Psychedelic Regulation: Tools, not Treatments In this new article, we propose to regulate psychedelics as psychotherapeutic treatment tools rather than as treatments in their own right. The use of anesthetics as treatment tools in surgery is a useful analogy.

Last year, @jacobsaday.bsky.social and @trpr-ucsf.bsky.social asked: "Psychedelic assisted psychotherapy: where is the psychotherapy research?" link.springer.com/article/10.1... How soon can we say "here it comes"?

Psychedelics could play a leading role in mental health care. But if approval is rushed without necessary guardrails in place, there will be a backlash, and these drugs will be relegated to the fringes of alternative health. That would be a tragic missed opportunity. www.nytimes.com/2025/04/28/o...

🚨 Postdoc Opportunity in Psychedelic Science Join a leading psychedelic research team at Johns Hopkins @jhpsychedelics.bsky.social. Design and lead experimental studies & clinical trials. Work with David Yaden, PhD & Sandeep Nayak, MD & others -Salary: Middling -Apply: [email protected] -Pls share!

“Addressing blinding in classic psychedelic studies with innovative active placebos” is out now in the International Journal of Neuropsychopharmacology. Co-first authored with Otto Simonsson, alongside Cyril D’Souza and Emmanuelle Schindler academic.oup.com/ijnp/advance...

We are thrilled to announce the launch of the 2025 Psychedelic Community Survey, a research project for the psychedelic community. Participation is completely anonymous. Please share the survey invitation and link with anyone you think might be interested in participating.

New pre-print out 🌍✨🌌 'Learning from Boundlessness: Psychedelic induced awe and epistemic shifts towards a holistic worldview' doi.org/10.21203/rs.... We explored how awe during psychedelic experiences relates to lasting shifts in sense of self, other, and reality

Our pilot clinical trial of psilocybin-assisted therapy for fibromyalgia was published today in Frontiers in Pain Research 🙂🍄 www.frontiersin.org/journals/pai...

My lab has a position for a programmer--if you have programming skills and have recently left the NIH please contact me.

Newest paper: #PsychedelicScience #Psychedelics

New articles from the Michigan Psychedelic Center: "Tripping into Treatment: Comparing Initial and Current Motivations for Psychedelic Use" "Psychedelics and chronic pain: self-reported outcomes on changed substance use patterns and health following naturalistic psychedelic use"

Just came across this fascinating 2024 DMT study I missed - participants who were interrupted during their DMT experience (by having to give ratings) showed significantly less reduction in depressive symptoms compared to those left undisturbed. Important implications for psychedelic therapy. 🧵

Latest twist in Lykos saga has it all: ✅ Takeover bid led by billionaire who took drugs with Elon + helped him buy X ✅ Potential involvement of biotech exec widely accused of price gouging ✅ But also the potential to return Lykos to its public benefit mission psychedelicalpha.com/news/billion...

Big co-1st/corresponding author paper just published in @JAMAPsychiatry! I just can't thank our team enough for their unwavering support on this project. Modifying Informed Consent to Help Address Functional Unmasking in Psychedelic Clinical Trials jamanetwork.com/journals/jam...

I spoke with Javier Muniz, MD, who just left his role as Associate Director at FDA's Division of Psychiatry, about all things psychedelics. psychedelicalpha.com/news/inside-...

Psychopharmacology gets lots of criticism from psychotherapy/adjacent folks. But if someone could send me therapy trials that 1. Are double-triple blind 2. Carefully document/report AEs 3. Pre-register an SAP with ITT I would appreciate. I will wait ….

A new preprint for my new BlueSky homies: "Major life changes following psychedelic use: A retrospective survey among people using psychedelics naturalistically" www.researchgate.net/publication/...